Trial · NCT07514936
Venetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid Leukaemia
NCT07514936, Phase 3, Recruiting, Chinese PLA General Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Venetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid Leukaemia. Trials, record NCT07514936. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07514936
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Venetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid Leukaemia
- NCT number
- NCT07514936
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 120 participants, estimated
- Lead sponsor
- Chinese PLA General Hospital
- Conditions
- Newly Diagnosed Acute Myeloid Leukemia (AML), Elderly Patients
- Interventions
- the standard "3+7" regimen, Azacytidine; Cytarabine; Aclacinomycin; Chidamide; Venetoclax; Granulocyte
- First posted
- 2026-04-07
- Last updated
- 2026-08-20
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Composite Complete Remission (CRc) Rate after 1 course of treatment | 1 months after study treatment | a combination of complete remission (CR) and complete remission with incomplete blood count recovery (CRi) |
| Secondary | Overall Response Rate (ORR) after 1 course of treatment | 1 months after the start of study treatment | Defined as the percentage of participants achieving a best overall response of complete response (CR), CR with incomplete blood count recovery (CRi), or partial response (PR).Biological characteristics exploratory studies were analyzed by single-cell sequencing and Atac-seq. Further, according to European LeukemiaNet risk group, we analyzed the outcomes of patients by molecular subtype as a sub-group analysis. |
| Secondary | Complete Remission (CR) Rate after 1 courses of treatment | after 1 courses of chemotherapy (each course is 28 days) | Defined in accordance with the IWG Response Criteria in AML. Bone marrow blasts\<5 percent; absence of blasts with Auer rods; absence of extramedullary disease; absolute neutrophil count \>1.0 x 10\^9/L (1000/µL); platelet count \>100 x 109/L (100,000/µL); independence of red cell transfusions. |
| Secondary | Rate of Minimal Residual Disease (MRD)-Negative Response | after each courses of chemotherapy (each course is 28 days) | Percentage of participants who achieved MRD-negative response, defined as \< 1 leukemia cell per 10,000 leukocytes as assessed by flow cytometry after each courses of chemotherapy (each course is 28 days) |
| Secondary | Event-free survival | 180 days after study treatment | Defined as the time interval from treatment initiation to the occurrence of induction failure,relapse,or death,whichever came first. |
| Secondary | Overall Survival | 180 days after study treatment | Defined as the time from joining the clinical study to death due to any cause. |
| Secondary | Treatment-related adverse events | From the first dose of study treatment to 30 days after the discontinuation of treatment | Defined as adverse events that occurred from the first dose of study treatment to 30 days after the discontinuation of treatment. |
| Secondary | Disease-free survival | 180 days after study treatment Outcome Measure | Defined as the time interval from disease remission to the occurrence of relapse or death,whichever came first. |
| Secondary | Early death | Within 30 days of the start of the first course of treatment | Defined as death within 30 days of chemotherapy. |
| Secondary | Complete Remission with Incomplete Blood Count Recovery (CRi)after 1 courses of treatment | after 1 courses of chemotherapy (each course is 28 days | Disappearance of leukemia blasts in the bone marrow (\<5% blasts) but without full recovery of blood counts (neutrophils \<1.0 x 10⁹/L and/or platelets \<100 x 10⁹/L). |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07514936
GET https://conductscience.org/api/trials/v1/NCT07514936/registered